Ebrahimkhani Mohammad R, Moezi Leila, Kiani Samira, Merat Shahin, Dehpour Ahmad R
Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran.
Dig Dis Sci. 2008 Nov;53(11):3007-11. doi: 10.1007/s10620-008-0261-7. Epub 2008 May 9.
Arterial vasodilation with concomitant hyperdynamic circulation is a common finding in cirrhotic subjects. Elevated levels of plasma endogenous opioid peptides have been reported in cholestasis and cirrhosis. Increased opioid peptides contribute to different manifestations of chronic liver disease such as pruritus, ascitis, and hepatic encephalopathy. In this study the potential role of opioid system in cirrhosis-induced vascular hyporesponsiveness was investigated. Bile duct ligated and sham operated animals received daily subcutaneous administration of naltrexone, an opioid receptor antagonist (20 mg/kg/day), or saline for 28 days. After 4 weeks the superior mesenteric artery was cannulated and was perfused according to McGregor method and then phenylephrine vasoconstrictor response of mesenteric vessels (10(-10) to 10(-6 )mol) was examined. In order to evaluate the effects of acute opioid receptor blockade, additional groups of animals were treated by acute single intraperitoneal naltrexone injection (20 mg/kg). Plasma level of nitrite/nitrate as an indicator for nitric oxide production was measured. Biliary cirrhosis was accompanied with a decrease in baseline perfusion pressure in mesenteric vascular bed (P < 0.01). Chronic opioid receptor blockade significantly increased this parameter (P < 0.01). The maximum pressure response to phenylephrine was decreased significantly in cirrhosis while chronic naltrexone treatment completely improved it (P < 0.01). Acute single injection of naltrexone could not influence the understudied homodynamic parameters. Chronic opioid receptor blockade did not modulate the increased nitrite/nitrate levels following cholestasis. This study provided evidence on the contribution of endogenous opioid system to vascular hyporesponsiveness in cirrhosis which is not directly correlated to high plasma NO levels.
动脉血管舒张伴高动力循环是肝硬化患者的常见表现。已有报道称胆汁淤积和肝硬化患者血浆内源性阿片肽水平升高。阿片肽增加会导致慢性肝病的不同表现,如瘙痒、腹水和肝性脑病。在本研究中,研究了阿片系统在肝硬化诱导的血管反应性降低中的潜在作用。胆管结扎和假手术动物每天皮下注射阿片受体拮抗剂纳曲酮(20mg/kg/天)或生理盐水,持续28天。4周后,将肠系膜上动脉插管并按照麦格雷戈方法进行灌注,然后检测肠系膜血管对去氧肾上腺素血管收缩剂的反应(10^(-10)至10^(-6)mol)。为了评估急性阿片受体阻断的效果,另外几组动物通过腹腔内单次注射纳曲酮(20mg/kg)进行治疗。测量血浆亚硝酸盐/硝酸盐水平作为一氧化氮产生的指标。胆汁性肝硬化伴有肠系膜血管床基线灌注压降低(P<0.01)。慢性阿片受体阻断显著增加了该参数(P<0.01)。肝硬化时对去氧肾上腺素的最大压力反应显著降低,而慢性纳曲酮治疗完全改善了这一反应(P<0.01)。单次急性注射纳曲酮不会影响所研究的血流动力学参数。慢性阿片受体阻断并未调节胆汁淤积后升高的亚硝酸盐/硝酸盐水平。本研究提供了证据,证明内源性阿片系统对肝硬化血管反应性降低有贡献,且这与高血浆一氧化氮水平无直接关联。